Hot Features
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-con... Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.06 | -4 | 1.5 | 1.57 | 1.37 | 51320 | 1.48410498 | CS |
| 4 | -0.08 | -5.26315789474 | 1.52 | 1.57 | 1.37 | 40742 | 1.49399594 | CS |
| 12 | -0.48 | -25 | 1.92 | 2.33 | 1.37 | 72131 | 1.82320972 | CS |
| 26 | 0.03 | 2.12765957447 | 1.41 | 2.33 | 1.23 | 96592 | 1.65325081 | CS |
| 52 | -0.47 | -24.6073298429 | 1.91 | 2.33 | 1.23 | 118755 | 1.60396824 | CS |
| 156 | 0.29 | 25.2173913043 | 1.15 | 4.26 | 0.91 | 106720 | 1.98492246 | CS |
| 260 | -1.5 | -51.0204081633 | 2.94 | 6.19 | 0.61 | 134804 | 2.27082155 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.